Back to top

gene-therapy: Archive

Zacks Equity Research

bluebird (BLUE) to Boost Cash With Priority Review Voucher Sale

bluebird (BLUE) is set to sell one of its two priority review vouchers. This will strengthen its financial position as its existing cash balance is expected to exhaust by second-quarter 2023.

BMYNegative Net Change BLUENegative Net Change RPTXNegative Net Change TSVTNegative Net Change

Zacks Equity Research

Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review

The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.

RHHBYNegative Net Change VRTXNegative Net Change ANGNPositive Net Change SRPTNegative Net Change

Zacks Equity Research

BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing

The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.

BMRNNegative Net Change VRTXNegative Net Change ANGNPositive Net Change CELUNegative Net Change